

Posttranslational Processing and Identification of a Neutralization Domain of the GP₄ Protein Encoded by ORF4 of Lelystad Virus

J. J. M. MEULENBERG,* A. P. VAN NIEUWSTADT, A. VAN ESSEN-ZANDBERGEN,
AND J. P. M. LANGEVELD

Institute for Animal Science and Health, NL-8200 AJ Lelystad, The Netherlands

Received 6 January 1997/Accepted 27 April 1997

GP₄ is a minor structural glycoprotein encoded by ORF4 of Lelystad virus (LV). When it was immunoprecipitated from cell lysates and extracellular virus of CL2621 cells infected with LV, it was shown to have an apparent molecular mass of approximately 28 and 31 kDa, respectively. This difference in size occurred because its core N-glycans were modified to complex type N-glycans during the transport of the protein through the endoplasmic reticulum and Golgi compartment. A panel of 15 neutralizing monoclonal antibodies (MAbs) reacted with the native GP₄ protein expressed by LV and the recombinant GP₄ protein expressed in a Semliki Forest virus expression system. However, these MAbs did not react with the GP₄ protein of U.S. isolate VR2332. To map the binding site of the MAbs, chimeric constructs composed of ORF4 of LV and VR2332 were generated. The reactivity of these constructs indicated that all the MAbs were directed against a region spanning amino acids 40 to 79 of the GP₄ protein of LV. Six MAbs reacted with solid-phase synthetic dodecapeptides. The core of this site consists of amino acids 59 to 67 (SAAQEKISF). Comparison of the amino acid sequences of GP₄ proteins from various European and North American isolates indicated that the neutralization domain spanning amino acids 40 to 79 is the most variable region of GP₄. The neutralization domain of GP₄, described here, is the first identified for LV.

Lelystad virus (LV) is the etiological agent of a disease, currently called porcine reproductive and respiratory syndrome, which causes abortions in sows and respiratory distress in piglets. It was first isolated in Europe in 1991 (33), whereas a virus that causes similar clinical symptoms was isolated in the United States in 1992 and was designated porcine reproductive and respiratory syndrome virus (4). LV is a small, enveloped virus containing a positive-strand RNA genome. It grows preferentially in macrophages but can also grow in vitro in cell line CL2621 and other cell lines cloned from the monkey kidney cell line MA-104 (3, 4, 15). The genome of LV, a polyadenylated RNA of approximately 15 kb, was first sequenced in 1993 (5, 24). The nucleotide sequence, genome organization, and replication strategy indicated that LV is related to a group of small enveloped positive-strand RNA viruses, designated arteriviruses (24). This new family of viruses includes lactate dehydrogenase-elevating virus (LDV), equine arteritis virus (EAV), and simian hemorrhagic fever virus. Arteriviruses contain a genome of 12.5 to 15 kb and synthesize a 3' nested set of six subgenomic RNAs during replication (6, 16, 23, 29, 34). These subgenomic RNAs contain a leader sequence which is derived from the 5' end of the viral genome. Open reading frame 1a (ORF 1a) and ORF1b make up approximately two-thirds of the viral genome and encode the RNA-dependent RNA polymerase. Six smaller ORFs, ORF2 to ORF7, are located at the 3' end of the viral genome. ORF2 to ORF6 probably encode envelope proteins, whereas ORF7 encodes the nucleocapsid protein (8–10, 26).

LV is the first arterivirus for which it has been demonstrated that all six proteins encoded by ORF2 to ORF7 are associated

with the virion (25, 31). The 15-kDa N protein (encoded by ORF7) and the 18-kDa integral membrane protein M (ORF6) are not N glycosylated, in contrast to the 29- to 30-kDa GP₂ protein (ORF2), the 45- to 50-kDa GP₃ protein (ORF3), the 31- to 35-kDa GP₄ protein (ORF4), and the 25-kDa GP₅ protein (ORF5), which are. The N, M, and GP₅ proteins have also been detected in extracellular virus and lysates of cells infected with North American isolates, which are antigenically different from LV (2, 22, 28).

In a previous report, we described the isolation and characterization of a panel of LV-specific monoclonal antibodies (MAbs) that recognized GP₃, GP₄, M, and N (31). Interestingly, the MAbs directed against GP₄ neutralized LV, suggesting that at least part of the protein is exposed at the virion surface. In the present study, we have further investigated the processing and antigenic sites of the GP₄ protein. Using chimeric genes and pepscan analysis, we identified an antigenic domain in GP₄ of LV that can elicit neutralizing antibodies. This domain was shown to be highly variable among other strains of LV.

MATERIALS AND METHODS

Cells and viruses. The European prototype *Ter Huurne* strain of LV was isolated in 1991 (33). The U.S. prototype VR2332 strain was isolated in 1992 by Benfield et al. (3). Strain NL1 (isolated in The Netherlands in 1991) was isolated in our institute. The other strains tested were kindly provided as follows: strain NY2 (isolated in England in 1991) by T. Drew, strain DEN (isolated in Denmark in 1992) by A. Botner, strain LUX (isolated in Luxemburg in 1992) by A. Losch, SPA1 (isolated in Spain in 1992) by V. Shokouhi, SPA2 (isolated in Spain in 1992) by L. Espuna, and strain FRA (isolated in France in 1992) by Y. Leforban.

LV and VR2332 were grown on CL2621 cells as described previously (31). The seven different European isolates were grown in porcine alveolar macrophages. Macrophages were maintained as described previously (33). BHK-21 cells were maintained in Dulbecco's minimal essential medium supplemented with 5% fetal bovine serum and antibiotics. For transfection experiments, the BHK-21 cells were grown in Glasgow minimal essential medium (GIBCO-BRL/Life Technologies Ltd.) by the method of Liljestrom and Garoff (21).

* Corresponding author. Mailing address: Institute for Animal Science and Health, P.O. Box 365, NL-8200 AJ Lelystad, The Netherlands. Phone: 31-320238805. Fax: 31-320238668. E-mail: J.J.M.Meulenber@id.dlo.nl.

TABLE 1. MAbs that reacted with GP₄ in Western blot analysis and were used in this study

| MAb | Isotype | Ig concn (μg/ml) | Antibody titer ^c | Neutralization ^b | PEPSCAN result ^c |
|--------|-----------------|------------------|-----------------------------|-----------------------------|-----------------------------|
| 121.4 | NT ^d | NT ^d | 1 | — | — |
| 122.1 | IgG2a | 87 | 256 | + | — |
| 122.12 | IgG1 | 87 | 512 | ++ | ± |
| 122.20 | IgG1 | 63 | 256 | ++ | — |
| 122.29 | IgG1 | 89 | 1,024 | +++ | + |
| 122.30 | IgG1 | 105 | 512 | +++ | + |
| 122.59 | IgG1 | 64 | 256 | ++ | — |
| 122.66 | IgG1 | 74 | 512 | ++ | + |
| 122.68 | IgG1 | 70 | 32 | ++ | — |
| 122.70 | IgG1 | 85 | 128 | ++ | — |
| 122.71 | IgG1 | 81 | 256 | +++ | + |
| 126.1 | IgG2b | 50 | 256 | +++ | — |
| 126.7 | IgG1 | 53 | 128 | ++ | — |
| 130.7 | IgG2a | 23 | 256 | +++ | + |
| 138.28 | IgG2b | 40 | 1,024 | +++ | + |

^a Reciprocal of the highest dilution of hybridoma cell culture medium positive in an indirect immunoperoxidase assay of lung alveolar macrophages infected with LV.

^b —, no plaque reduction by undiluted hybridoma medium; +, >50% plaque reduction by undiluted hybridoma medium; ++, >50% plaque reduction by undiluted and 1:10-diluted hybridoma medium; +++, >50% plaque reduction by undiluted, 1:10-diluted, and 1:100-diluted hybridoma medium.

^c Reactivity of MAbs with the core sequence (SAAQEKISF; amino acids 59 to 67) in the PEPSCAN analysis; +, positive; —, negative; ±, weak.

^d NT, the Ig production of this MAb was too low to determine its concentration and its isotype.

Antisera. Porcine anti-LV serum 21 and rabbit antipeptide serum 698 (directed against amino acids 62 to 77 of GP₄) have been used in previous experiments (26). Serum 700 is directed against amino acids 106 to 122 (CLFYASEMSEKGFVKVIF) of GP₄ of LV and was obtained from a rabbit immunized as described previously (26). The production and characterization of four MAbs directed against the GP₄ protein have been described by van Nieuwstadt et al. (31). In addition to these, 11 other GP₄-specific MAbs were generated by immunizing mice with purified LV virions (31) and are listed in Table 1. The hybridomas producing these MAbs were derived from five consecutive fusion experiments: (i) MAb 121.4; (ii) MAbs 122.1, 122.12, 122.20, 122.29, 122.30, 122.59, 122.66, 122.68, 122.70, and 122.71; (iii) MAbs 126.1 and 126.7; (iv) MAb 130.7; and (v) MAb 138.28. The neutralizing activity of these MAbs was tested in a plaque reduction assay as described previously (31).

Plasmid constructions. Two oligonucleotides located upstream (LV13) and downstream (LV14) of ORF4 have been used previously to amplify and clone ORF4 in pGEM-4Z with the *Bam*HI and *Hind*III sites introduced in the primers (26). Table 2 shows the sequences of these primers and the primers listed below. The resulting plasmid was named pABV209. Two oligonucleotides, located at a similar position in relation to the initiation codon (PRRSV4) and the termination codon (PRRSV5) of ORF4 of VR2332 were used in reverse transcription-PCR (23) to amplify ORF4 of VR2332. The PCR fragment was digested with *Bam*HI and partially digested with *Hind*III, because ORF4 of VR2332 contains an internal *Hind*III site. The fragment was then cloned in pGEM-4Z, resulting in plasmid pABV270. Recombinant DNA techniques were performed essentially as described by Sambrook et al. (30). The nucleotide sequence of VR2332 ORF4 in pABV270 was determined on an automated DNA sequencer (Applied Biosystems) and was found to be identical to the published sequence (27). The ORF4 genes of LV and VR2332 were then transferred to the Semliki Forest virus expression vector pSFV1. Plasmids pABV209 and pABV270 were digested with *Bam*HI and *Hind*III (only partially for pABV270), the ORF4 fragments were treated with Klenow polymerase (Pharmacia) to create blunt ends, and these were then ligated in the *Sma*I site of pSFV1, which was dephosphorylated with calf intestinal alkaline phosphatase (Pharmacia). Plasmids containing ORF4 of LV (pABV265) and VR2332 (pABV271) in the correct orientation were further tested for expression of the GP₄ protein (see Fig. 3).

In addition, four different chimeric ORF4 genes of LV and VR2332 were made by using PCR to amplify fragments of pABV209 and pABV270 with primers containing the appropriate restriction sites to ligate the fragments in pGEM-4Z (see Fig. 3). The nucleotide sequence of ORF4 encoding amino acids 1 to 39 of the GP₄ protein of VR2332 was amplified with oligonucleotides PRRSV4 and PRRSV6 and was exchanged for that encoding amino acids 1 to 39 of LV in pABV209. This resulted in pABV306. The nucleotide sequence of ORF4 encoding amino acids 1 to 75 of GP₄ of VR2332 was amplified with oligonucleotides PRRSV4 and PRRSV9 and was ligated to the nucleotide sequence of ORF4 encoding amino acids 80 to 183 of the LV GP₄ protein, amplified with LV46 and LV14. This resulted in plasmid pABV308. In the same

way, a complementary construct was created in pGEM-4Z; it consisted of the nucleotide sequence encoding amino acids 1 to 79 of the LV GP₄ protein amplified with LV13 and LV57 ligated to a fragment encoding amino acids 76 to 178 of VR2332, which was amplified with PRRSV10 and PRRSV5. This resulted in plasmid pABV314. A fourth chimeric construct consisted of a fragment encoding amino acids 40 to 79 of the LV GP₄ protein fused to fragments encoding amino acids 1 to 39 and amino acids 76 to 178 of the VR2332 GP₄ protein. This was achieved by ligating the *Bam*HI-*Sac*II ORF4 fragment of pABV270 and the *Sac*II-*Hind*III ORF4 fragment of pABV314 in pGEM-4Z digested with *Bam*HI and *Hind*III. This resulted in plasmid pABV325. Oligonucleotide sequencing was used to check plasmids pABV306, pABV308, pABV314, and pABV325 for the correct sequence. The chimeric ORF4 genes were transferred from pABV306, pABV308, pABV314, and pABV325 to pSFV1, as described above for the ORF4 genes of pABV209 and pABV270, resulting in pABV296, pABV305, pABV321, and pABV326, respectively (see Fig. 3).

To clone the ORF4 genes of seven different European isolates, we infected macrophages with NL1, NY2, DEN, FRA, SPA1, SPA2, and LUX. RNA was isolated as described by Meulenber et al. (24). The ORF4 genes were amplified by reverse transcription PCR with oligonucleotides LV13 and LV14 by the method we used in an earlier study (23) and were cloned with *Bam*HI and *Hind*III in pGEM-4Z. For each strain, the nucleotide sequence of ORF4 of two clones derived from two independent PCRs was determined. The amino acid sequences derived from the nucleotide sequence were aligned with the multiple-sequence alignment program CLUSTAL of PCGene (IntelliGenetics Tm).

In vitro transcription and transfection of Semliki Forest virus ORF4 RNA. The pSFV1 plasmids containing different ORF4 constructs were linearized by digestion with *Spe*I and transcribed in vitro by the method of Liljeström and Garoff (20, 21). The synthesized RNA was transfected to BHK-21 cells in 15-mm wells of 24-well plates with Lipofectin as described by Liljeström and Garoff (21). Cells were fixed with ice-cold 50% (vol/vol) methanol-acetone, and the GP₄ protein expressed by the various ORF4 constructs was stained with MAbs in the immunoperoxidase monolayer assay (IPMA), essentially as described by Wensvoort et al. (32). To analyze the ORF4 expression products by immunoprecipitation, we transfected 10⁷ BHK-21 cells with 10 μg of Semliki Forest virus ORF4 RNA (in vitro transcribed) by electroporation by the method of Liljeström and Garoff (21). The electroporated cells were plated in three 35-mm wells of six-well plates and labeled 18 h after transfection.

Radioactive labeling of proteins. BHK-21 cells electroporated with RNA derived from the various ORF4 constructs in pSFV1 were starved for 30 min in methionine-free Eagle's basal medium and were then labeled with 120 μCi of L-[³⁵S]methionine per ml for 4 h. Lysates were prepared as described by Meulenber et al. (26) and were used for immunoprecipitation.

Metabolic labeling of CL2621 cells infected with LV and pulse-chase experiments were performed as described previously (25).

Immunoprecipitation, endoglycosidase treatment, and gel electrophoresis. Proteins were immunoprecipitated essentially by the method of Hulst et al. (14). Immunoprecipitates of LV proteins were either directly resuspended in Laemmli sample buffer (17) or were pretreated with endoglycosidases before being resuspended. In the latter treatment, the samples were resuspended in the appropriate endoglycosidase buffer and treated with peptide-N-glycosidase F (PNGase F; Boehringer Mannheim) or endo-β-N-acetyl-D-glucosaminidase H (Endo H; Boehringer Mannheim) as described previously (26). Controls were treated similarly, except that the PNGase F or Endo H was omitted. Samples were resuspended in Laemmli sample buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

TABLE 2. Sequence of primers used in PCR to clone the ORF4 genes of LV and VR2332 and chimeric ORF4 genes in plasmid vectors pGEM-4Z and pSFV1

| Name | Sequence ^a | Incorporated restriction site |
|---------|---------------------------------------|-------------------------------|
| LV13 | 5' GGCAATTGGATCCATTGGGA 3' | <i>Bam</i> HI |
| LV14 | 5' AGAAGCAAGCTTGC GGAGTC 3' | <i>Hind</i> III |
| LV46 | 5' GCCGTCGGTACCCCTCAGTACAT 3' | <i>Kpn</i> I |
| LV57 | 5' ATGTA CTGAGGGGTACCGACGGC 3' | <i>Kpn</i> I |
| PRRSV4 | 5' GGCAATTGGATCCACCTAGAAATGGC 3' | <i>Bam</i> HI |
| PRRSV5 | 5' GCGAGCAAGCTTCCCGCTCAAGCATTCT 3' | <i>Hind</i> III |
| PRRSV6 | 5' CTTGCCGC CGGGTGGTGTG 3' | <i>Sac</i> II |
| PRRSV9 | 5' ACAGCTGGTACCTATCGCCGTACGGCACTGA 3' | <i>Kpn</i> I |
| PRRSV10 | 5' GCGATAGG TACCCCTGTGTATGTACCAT 3' | <i>Kpn</i> I |

^a The underlined nucleotides in these primers are mutated with respect to the original sequence to create restriction sites or overhanging sequences or to avoid long stretches of one particular nucleotide. The restriction sites in the primers are shown in italics.




FIG. 1. Immunoprecipitation of GP₄ from lysates and extracellular virus of CL2621 cells infected with LV. For the preparation of radiolabeled cell lysates, CL2621 cells were infected with LV, and 18 h after infection they were labeled for 4 h with 90 μ Ci of L-[³⁵S]methionine per ml. For the preparation of radiolabeled virus, CL2621 cells were labeled between 8 and 32 h after LV infection with 60 μ Ci of L-[³⁵S]methionine per ml. (a) Cell lysates (CL) and extracellular virus (EV) of LV-infected (LV +), or mock-infected (LV -) CL2621 cells were immunoprecipitated with anti-GP₄ MAb 126.1. The position of the GP₄ protein is indicated by arrows. (b) Immunoprecipitation of GP₄ with MAb 126.1 from cell lysates (CL) and extracellular virus (EV) of CL2621 cells infected with LV. The immunoprecipitated GP₄ protein was either untreated (U), PNGase F treated (F), or Endo H treated (H). The samples were analyzed in an SDS-12.5% polyacrylamide gel under reducing conditions. The positions of the molecular weight markers are indicated on the left in thousands.

Epitope mapping by PEPSCAN procedures. A complete set of solid-phase overlapping dodecapeptides was synthesized from amino acids 25 to 94 of the ORF4 sequence of LV, which was determined previously (24). The synthesis of solid-phase peptides on polyethylene rods and immunoscreening by an enzyme-linked immunosorbent assay type of analysis were carried out by established PEPSCAN procedures (11). The hybridoma cell culture media were tested at a 1:5 dilution. Peptides were considered to represent antigenic sites if absorbance signals of two or more neighbouring peptides reproducibly amounted to more than twice the background.

RESULTS

Processing of GP₄. In an earlier study, we described a panel of neutralizing MAbs that reacted in Western immunoblot analysis with a diffuse 31- to 35-kDa protein of LV, which we designated GP₄ (31). GP₄ was shown to be a structural glycoprotein encoded by ORF4. In the present study, we used the

immunoprecipitation technique to further investigate the processing of the GP₄ protein and to compare the GP₄ protein present in cell lysates and extracellular virus of CL2621 cells infected with LV. The GP₄ protein was immunoprecipitated by GP₄-specific MAb126.1 from lysates of LV-infected cells but not from lysates of mock-infected cells and migrated as a discrete band of 28 kDa together with a faint smear of somewhat higher apparent molecular mass (Fig. 1A). MAb 126.1 immunoprecipitated a diffuse GP₄ protein of about 31 kDa from the extracellular medium of LV-infected cells but not from the extracellular medium of mock-infected cells (Fig. 1A). The 15-kDa N protein was nonspecifically immunoprecipitated, as observed in previous immunoprecipitation experiments (25). The precipitation of N is not a result of a specific interaction between N and GP₄, because MAbs against N do not coprecipitate GP₄. When the immunoprecipitates were treated with PNGase F (an endoglycosidase that cleaves all N glycans irrespective of their maturation state) and with Endo H (an endoglycosidase that cleaves only noncomplex type N glycans), the GP₄ protein present in cell lysates was sensitive to both PNGase F and Endo H whereas the GP₄ protein present in extracellular virus was sensitive to PNGase F but resistant to Endo H (Fig. 1B). These findings indicate that the high-mannose N glycans of GP₄ had been modified to complex type N glycans during transport through the Golgi compartment, resulting in a more diffuse protein with a higher molecular mass (Fig. 1B). The difference in molecular mass between the PNGase F-treated and mock-treated GP₄ protein (approximately 10 kDa) suggests that all four putative N-glycosylation sites present in the amino acid sequence are used *in vivo*. A pulse-chase labeling experiment was performed to study the kinetics of the acquisition of Endo H-resistant N-glycans. The GP₄ protein migrated as a discrete band of 28 kDa after the pulse but faded during the chase, while a diffuse and slower-migrating species appeared (Fig. 2). The GP₄ protein was sensitive to PNGase F after the pulse but gradually became resistant to Endo H. After a chase of 180 min, most of the N glycans of the GP₄ protein had been converted to complex type N glycans. When the chase period was 400 min, the overall intensity of the GP₄ protein was significantly decreased, which may reflect the incorporation of this protein into virus particles followed by secretion of these particles into the medium (data not shown).

Identification of a neutralization domain in GP₄. In an earlier study, we demonstrated that four neutralizing MAbs specific for the GP₄ protein recognized LV but did not recognize




FIG. 2. Acquisition of Endo H resistance by the GP₄ protein. CL2621 cells were infected with LV, and 18 h after infection they were pulse-labeled for 30 min with 600 μ Ci of L-[³⁵S]methionine per ml and chased in medium containing 5 mM nonradioactive methionine. The length of the chase is indicated in minutes above the lanes. Lysates were prepared and immunoprecipitated with MAb 126.1. The immunoprecipitated proteins were treated with PNGase F (F) or Endo H (H) or were left untreated (U) before analysis by SDS-PAGE on a gel containing 12.5% acrylamide. The numbers on the left show the sizes of marker proteins in kilodaltons.




FIG. 3. Schematic diagram of GP₄ proteins expressed in pSFV1 and their reactivity with GP₄-specific MAbs. The names of the plasmids containing the different ORF4 genes are indicated. The genes were first inserted in PGEM-4Z and then transferred to pSFV1, as described in detail in Materials and Methods. Open bars represent the amino acid sequences derived from the GP₄ protein encoded by ORF4 of LV, and solid bars represent amino acid sequences derived from the GP₄ protein encoded by ORF4 of VR2332. The numbers of the amino acids are indicated above the bars and are derived from the amino acid sequences of GP₄ of LV and VR2332, as shown in Fig. 6B. The complete set of 15 GP₄-specific MAbs reacted identically with the different constructs in IPMA, and the reactivity is indicated as positive (+) or negative (-).

the U.S. isolate VR2332 (31). Besides these four MAbs, 11 other neutralizing GP₄-specific MAbs that had the same strain specificity were developed (Table 1). To identify the binding domain of these MAbs in the GP₄ protein, we made chimeric proteins of the GP₄ protein of LV and the U.S. isolate VR2332. These proteins were expressed in the Semliki Forest virus expression system developed by Liljeström and Garoff (20). First, RNA transcribed from pABV265, which consists of ORF4 of LV cloned in pSFV1, was transfected to BHK-21 cells, and 24 h later the cells were positively stained with each of a panel of 15 neutralizing MAbs in IPMA (Fig. 3), whereas BHK-21 cells transfected with pSFV1-RNA were not stained with the MAbs (data not shown). The GP₄ protein of U.S. isolate VR2332, cloned in pSFV1, was not recognized by the MAbs upon expression in BHK-21 cells (Fig. 3). Next, four chimeric genes of ORF4 of LV and VR2332 were constructed in pSFV1, which resulted in plasmids pABV296, pABV305, pABV321, and pABV326 (Fig. 3). When RNAs transcribed from these plasmids were transfected to BHK-21 cells and tested in IPMA with the GP₄-specific MAbs, these MAbs reacted identically (Fig. 3). The reaction pattern indicated that the binding sites of these 15 GP₄-specific MAbs were located in a region spanning amino acids 40 to 79 of the GP₄ protein, since the expression product of pABV326, consisting of amino acids 40 to 79 derived from the LV GP₄ protein and flanking sequences derived from the VR2332 GP₄ protein, was still recognized by the panel of MAbs.

To ensure that the different GP₄ proteins, especially those that were not recognized by the MAbs, were properly expressed in BHK-21 cells, they were immunoprecipitated from

lysates of BHK-21 cells that were transfected with RNA transcribed in vitro from plasmids pABV265, pABV271, pABV296, pABV305, pABV321, and pABV326. Antipeptide serum 700 precipitated all six recombinant GP₄ proteins (Fig. 4). This was expected, since serum 700 is directed against amino acids 106 to 122 of the LV GP₄ protein, a sequence which, apart from amino acid 121, is identical in the VR2332 GP₄ protein. The recombinant GP₄ proteins had a similar size to the authentic GP₄ protein synthesized in CL2621 cells infected with LV (compare Fig. 2 and 4) and also contained PNGase F- and Endo H-sensitive N glycans (data not shown). The GP₄ proteins expressed by pABV305 and pABV271 migrated slightly faster than those expressed by pABV265, pABV296, pABV321, and pABV326, which is probably due to the deletion of 4 amino acids between amino acids 62 and 65 in the VR2332 sequence with respect to the LV sequence (as will be discussed in more detail below). MAb 126.1, specific to GP₄, recognized the GP₄ proteins expressed by pABV265, pABV296, pABV321, and pABV326 but did not recognize those expressed by pABV305 and pABV271, which confirmed the results obtained by IPMA (Fig. 3). Serum 698 had the same reaction profile as the MAbs. It contains antibodies that are directed against amino acids 62 to 77 of GP₄ of LV (26), which are located within the neutralizing domain of the GP₄ protein. Since the amino acid sequence in this region is completely different in VR2332 GP₄, the expression products containing the VR2332 sequence in this region were not recognized by this serum. Serum 21 recognized the LV GP₄ protein and the chimeric LV-VR2332 GP₄ proteins but did not recognize the VR2332 GP₄ protein. This indicated that this porcine anti-LV serum contains a variety of antibodies directed against different regions of the GP₄ protein.

Since the 15 MAbs all recognized the expression product of pABV326 and reacted with the reduced and denatured GP₄ protein in the Western blot analysis, they were expected to recognize a linear epitope in a region spanning amino acids 40 to 79 of GP₄. Therefore, their fine specificity was further investigated with synthetic peptides (12-mers) from this region by PEPSCAN analysis. MAbs 122.29, 122.30, 122.66, 122.71, 130.7, and 138.28 reacted positively with one specific antigenic site, consisting of amino acids 59 to 67 (SAAQEKISF) (Fig. 5). MAb 122.12 reacted only weakly with this antigenic site, whereas the remaining eight MAbs were negative in the PEPSCAN analysis.

Sequence analysis of the GP₄ protein of other European isolates. To analyze whether the antigenic domain, recognized by the GP₄-specific MAbs, was conserved among European isolates, the reactivity and neutralizing activity of the MAbs were further tested on seven European strains. The results indicated that these MAbs recognized and neutralized another Dutch isolate (NL1) and an English isolate (NY2) but not a Danish isolate (DEN), two Spanish isolates (SPA1 and SPA2),




FIG. 4. Immunoprecipitation of GP₄ proteins of LV and VR2332 and chimeric GP₄ proteins derived from them. The plasmids pABV265, pABV296, pABV305, pABV321, pABV326, and pABV271 used to express the GP₄ proteins are indicated. The RNA transcribed from these plasmids was transfected to BHK-21 cells, and these cells were labeled with L-[³⁵S]methionine. Cell lysates were prepared and were immunoprecipitated with GP₄-specific antipeptide sera 689 and 700, MAbs 126.1, and porcine anti-LV serum 21. The immunoprecipitated proteins were analyzed by SDS-PAGE on a gel containing 12.5% acrylamide. The numbers on the left show the sizes of marker proteins in kilodaltons.

four N-glycosylation sites found in the amino acid sequence are probably used *in vivo* and that the core N glycans are converted very slowly to complex-type N glycans during transport from the endoplasmic reticulum through the Golgi compartment. All the MABs recognized an antigenic site located between amino acids 40 and 79 of GP₄ of LV. In the PEPSCAN analysis, only six MABs recognized a more defined area between amino acids 59 and 67 (SAAQEKISF), whereas the other nine MABs did not react. MABs are expected to differ in specificity since they are produced from independent hybridomas and thus should have a variable genetic constitution (18). Perhaps the affinity of the MABs that did not react with linear peptides in the PEPSCAN analysis is too low, or their binding is more conformation dependent. Alternatively, they may recognize discontinuous epitopes adjacent to, partially overlapping with, or interacting with amino acids 59 to 67. Although all the MABs recognized the reduced GP₄ protein in Western blot analysis, suggesting that they recognize linear epitopes, the GP₄ protein might be partially refolded during the blotting procedure. Preliminary results in competitive binding assays showed that the binding to GP₄ of a MAB that reacted with peptides containing the core sequence SAAQEKISF in the PEPSCAN analysis was blocked by MABs that did not react with these peptides in the PEPSCAN analysis. This further supports our view that the antibody-binding sites of the 15 GP₄-specific MABs are partially overlapping or in physical proximity. Interestingly, the 15 MABs did not recognize and neutralize strain LUX, which had only three amino acid differences in the neutralization domain at positions 53, 57, and 64 of GP₄ compared to LV. This implies that amino acid 64 is most probably important for binding of the six MABs that reacted with the core sequence spanning amino acids 59 to 67 in the PEPSCAN analysis, whereas at least one of these three amino acids is also important for binding of the nine MABs that were negative in the PEPSCAN analysis. Further evidence for the importance of these amino acids for binding of the MABs should be obtained by introducing single amino acid mutations at these positions in GP₄ of LV. It is not very likely that the glycosylation of the GP₄ protein plays a role in the binding of the MABs since the N-glycosylation sites are located outside amino acids 40 to 79 and we have shown previously for a few GP₄-specific MABs that they recognize the deglycosylated GP₄ protein in Western blot analysis (31).

Since the MABs had neutralizing activity, their binding site is expected to be exposed at the viral surface. This is in line with the features characteristic for typical class I integral membrane proteins, which were identified in the amino acid sequence of GP₄. The N-terminal hydrophobic amino acids (amino acids 1 to 17) are expected to function as a signal sequence and might be cleaved off, whereas the hydrophobic amino acids (165 to 183) at the C terminus might anchor the protein in the membrane (26). The region in between, encompassing the antigenic domain identified here, is predicted to represent the ectodomain of the protein. The fact that 15 MABs derived from five independent fusions of splenocytes from mice immunized with purified LV virions all recognized a region between amino acids 40 and 79 of GP₄ suggests that this is an immunodominant domain. However, it should be noted that the probability of isolating hybridoma clones which produce antibodies to a given epitope may be influenced by factors other than the immunogenicity of the epitope, such as fusion efficiency and clone stabilization. In addition, the recognition of an antigenic site might be species specific, as was shown for the capsid proteins of canine parvovirus (19). Therefore, the immunogenic significance of this epitope for pigs should be investigated further. Preliminary results indicated that certain por-

cine sera that are positive for LV also reacted in the PEPSCAN analysis with peptides at the neutralization site.

Comparison of the amino acid sequence of the GP₄ proteins of various European strains indicated that the neutralization domain was much more variable than other parts of the protein, suggesting that this domain is susceptible to immunoselection. Comparison of the GP₄ sequences of European and North American strains revealed a gap of 4 amino acids at the neutralization site in the North American sequence in comparison with the European sequences. Therefore, it remains to be investigated whether the conformation in this region of GP₄ is similar in North American strains and European strains and whether this region of North American strains is also able to induce neutralizing antibodies.

The neutralization domain of the GP₄ protein described here is the first site identified for LV. For two other arteriviruses, EAV and LDV, the neutralizing MABs that were isolated were all directed against the major envelope protein G₁/VP3 encoded by ORF5 (1, 7, 12, 13). Therefore the G₁/VP3 protein is thought to interact with the receptor for EAV and LDV, respectively. By using neutralization-escape mutants, the neutralization site of EAV was mapped to specific amino acids in the ectodomain of G₁. Since GP₅ is also the major structural envelope protein of LV (26) and has a similar hydrophobicity profile to G₁/VP3, it might also be the protein that interacts with the receptor. Although porcine anti-LV sera recognize the GP₅ protein, we have not been able to isolate (neutralizing) MABs against GP₅ of LV. If GP₅ interacts with the receptor of LV, the GP₄ protein might be in close proximity to it, since anti-GP₄ MABs neutralize the virus. Future LV research should assess the role of GP₄, in particular its neutralization domain, and the role of GP₅ in immunity, cell attachment, and infection.

ACKNOWLEDGMENTS

Part of this work was supported by Boehringer Ingelheim, Germany, and the Produktschap voor Vee en Vlees (PVV), the Netherlands. We thank R. Moormann for critical reading of the manuscript.

REFERENCES

- Balasuriya, U. B. R., N. J. Maclachlan, A. A. F. de Vries, P. V. Rossito, and P. J. M. Rottier. 1995. Identification of a neutralization site in the major envelope glycoprotein (G₁) of equine arteritis virus. *Virology* **207**:518-527.
- Bautista, E. M., J. J. M. Meulenberg, C. S. Choi, and T. W. Molitor. 1996. Structural polypeptides of the American (VR-2332) strain of porcine reproductive respiratory syndrome virus. *Arch. Virol.* **141**:1357-1365.
- Benfield, D. A. E., E. Nelson, J. E. Collins, L. Harris, S. M. Goyal, D. Robison, W. T. Christianson, R. B. Morrison, D. E. Gorcyca, and D. W. Chladek. 1992. Characterization of swine infertility and respiratory syndrome virus (isolate ATCC-VR2332). *J. Vet. Diagn. Invest.* **4**:127-133.
- Collins, J. E., D. A. Benfield, W. T. Christianson, L. Harris, J. C. Hennings, D. P. Shaw, S. M. Goyal, S. McCullough, R. B. Morrison, H. S. Joo, D. E. Gorcyca, and D. W. Chladek. 1992. Isolation of swine infertility and respiratory syndrome virus (isolate ATCC-VR-2332) in North America and experimental reproduction of the disease in gnotobiotic pigs. *J. Vet. Diagn. Invest.* **4**:117-126.
- Conzelmann, K. K., N. Visser, P. van Woensel, and H. J. Tiel. 1993. Molecular characterization of porcine reproductive and respiratory syndrome virus, a member of the Arterivirus group. *Virology* **193**:329-339.
- den Boon, J. A., E. J. Snijder, E. D. Chirnside, A. A. F. de Vries, M. C. Horzinek, and W. J. M. Spaan. 1991. Equine arteritis virus is not a togavirus but belongs to the coronavirus superfamily. *J. Virol.* **65**:2910-2920.
- Deregt, D., A. A. F. de Vries, M. J. B. Raamsman, L. D. Elmgren, and P. J. M. Rottier. 1994. Monoclonal antibodies to Equine arteritis virus proteins identify the large envelope glycoprotein (G₁) as a target for virus neutralization. *J. Gen. Virol.* **75**:2439-2444.
- de Vries, A. A. F., E. D. Chirnside, M. C. Hozinek, and P. J. M. Rottier. 1992. Structural proteins of equine arteritis virus. *J. Virol.* **66**:6294-6303.
- Faaberg, K. S., C. Even, G. A. Palmer, and P. G. W. Plagemann. 1995. Disulfide bonds between two envelope proteins of lactate dehydrogenase-elevating virus are essential for viral infectivity. *J. Virol.* **69**:613-617.
- Faaberg, K. S., and P. G. W. Plagemann. 1995. The envelope proteins of

- lactate dehydrogenase-elevating virus and their membrane topography. *Virology* **212**:512–525.
11. Geysen, H. M., H. Meloen, and S. J. Barteling. 1998. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. *Proc. Natl. Acad. Sci. USA* **81**:3998–4002.
 12. Glaser, A. L., A. A. F. de Vries, and E. J. Dubovi. 1995. Comparison of equine arteritis virus isolates using neutralizing monoclonal antibodies and identification of sequence changes in G₁ associated with neutralization resistance. *J. Gen. Virol.* **76**:2223–2233.
 13. Harty, J. T., and P. G. W. Plagemann. 1988. Formalin inactivation of the lactate dehydrogenase-elevating virus reveals a major neutralizing epitope not recognized during natural infection. *J. Virol.* **62**:3210–3216.
 14. Hulst, M. M., D. F. Westra, G. Wensvoort, and R. J. M. Moormann. 1993. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. *J. Virol.* **67**:5435–5442.
 15. Kim, H. S., J. Kwang, and I. Y. Yoon. 1993. Enhanced replication of porcine reproductive and respiratory syndrome virus in a homogeneous subpopulation of MA-104 cell line. *Arch. Virol.* **133**:477–483.
 16. Kuo, L., J. T. Harty, L. Erickson, G. A. Palmer, and P. G. W. Plagemann. 1991. A nested set of eight RNAs is formed in macrophages infected with lactate dehydrogenase-elevating virus. *J. Virol.* **65**:5118–5123.
 17. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (London)* **227**:680–685.
 18. Langedijk, J. P. M., N. K. T. Back, E. Kinney-Thoma, C. Bruck, M. Francotte, J. Goudsmit, and R. H. Meloen. 1992. Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. *Arch. Virol.* **126**:129–146.
 19. Langeveld, J. P. M., J. I. Casal, C. Vela, K. Dalsgaard, S. Smale, W. Puijk, and R. H. Meloen. 1993. B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface. *J. Virol.* **67**:765–772.
 20. Liljeström, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. *Bio/technology* **9**:1356–1361.
 21. Liljeström, P., and H. Garoff. 1993. Expression of proteins using Semliki Forest virus vectors, p. 16.xx.1–16.xx.00. *In* F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. A. Smith, J. G. Seidman, and K. Struhl (ed.), *Current protocols in molecular biology*, Greene Publishing Associates and Wiley Interscience, New York, N.Y.
 22. Mardassi, H., B. Massie, and S. Dea. 1996. Intracellular synthesis, processing and transport of proteins encoded by ORFs 5 to 7 of porcine reproductive and respiratory syndrome virus. *Virology* **221**:98–112.
 - 22a. Meulenberg, J. Unpublished results.
 23. Meulenberg, J. J. M., E. J. de Meijer, and R. J. M. Moormann. 1993. Subgenomic RNAs of Lelystad virus contain a conserved junction sequence. *J. Gen. Virol.* **74**:1697–1701.
 24. Meulenberg, J. J. M., M. M. Hulst, E. J. de Meijer, P. L. J. M. Moonen, A. den Besten, E. P. de Kluyver, G. Wensvoort, and R. J. M. Moormann. 1993. Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS) is related to LDV and EAV. *Virology* **192**:62–74.
 25. Meulenberg, J. J. M., and A. Petersen-den Besten. 1996. Identification and characterization of a sixth structural protein of Lelystad virus: the glycoprotein GP₂ encoded by ORF2 is incorporated in virus particles. *Virology* **225**:44–51.
 26. Meulenberg, J. J. M., A. Petersen-den Besten, E. P. de Kluyver, R. J. M. Moormann, and G. Wensvoort. 1995. Characterization of proteins encoded by ORFs 2 to 7 of Lelystad virus. *Virology* **206**:155–163.
 27. Murtaugh, M. P., M. R. Elam, and Kakach. 1995. Comparison of the structural protein coding sequences of the VR-2332 and Lelystad virus strains of the PRRS virus. *Arch. Virol.* **140**:1451–1460.
 28. Nelson, E. A., J. Christopher-Hennings, T. Drew, G. Wensvoort, J. E. Collins, and D. A. Benfield. 1993. Differentiation of United states and european isolates of porcine reproductive and respiratory syndrome virus by monoclonal antibodies. *J. Clin. Microbiol.* **31**:3184–3189.
 29. Plagemann, P. G. W., V. and Moennig. 1991. Lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses. *Adv. Virus Res.* **41**:99–192.
 30. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
 31. van Nieuwstadt, A. P., J. J. M. Meulenberg, A. van Essen-Zandbergen, A. Petersen-den Besten, R. J. Bende, R. J. M. Moormann, and G. Wensvoort. 1996. Proteins encoded by ORFs 3 and 4 of the genome of Lelystad virus (Arteriviridae) are structural proteins of the virion. *J. Virol.* **70**:4767–4772.
 32. Wensvoort, G., C. Terpstra, J. Boonstra, M. Bloemraad, and D. van Zaane. 1986. Production of monoclonal antibodies against swine fever virus and their use in laboratory diagnosis. *Vet. Microbiol.* **12**:101–108.
 33. Wensvoort, G., C. Terpstra, J. M. A. Pol, E. A. ter Laak, M. Bloemraad, E. P. de Kluyver, C. Kragten, L. van Buiten, A. den Besten, F. Wagenaar, J. M. Broekhuijsen, P. L. J. M. Moonen, T. Zetstra, E. A. de Boer, H. J. Tibben, M. F. de Jong, P. van 't Veld, G. J. R. Groenland, J. A. van Gennep, M. T. Voets, J. H. M. Verheijden, and J. Braamskamp. 1991. Mystery swine disease in the Netherlands: the isolation of Lelystad virus. *Vet. Q.* **13**:121–130.
 34. Zeng, L., E. K. Godeny, S. L. Methven, and M. A. Brinton. 1995. Analysis of simian hemorrhagic fever virus (SHFV) subgenomic RNAs, junction sequences and 5' leader. *Virology* **207**:543–548.